Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135551605> ?p ?o ?g. }
- W3135551605 endingPage "300" @default.
- W3135551605 startingPage "287" @default.
- W3135551605 abstract "The rate of alcohol-related mortality in people experiencing homelessness and alcohol use disorder is high and necessitates accessible and effective treatment for alcohol use disorder. However, typical abstinence-based treatments do not optimally engage this population. Recent studies have shown that harm-reduction treatment, which does not require abstinence, but instead aims to incrementally reduce alcohol-related harm and improve health-related quality of life, is acceptable to and effective for this population. The aim of this study was to test the efficacy of combined pharmacological and behavioural harm-reduction treatment for alcohol use disorder (HaRT-A) in people experiencing homelessness and alcohol use disorder.This randomised clinical trial was done at three community-based service sites (low-barrier shelters and housing programmes) in Seattle (WA, USA). Eligible participants were adults (aged 21-65 years) who met the DSM-IV-TR criteria for alcohol use disorder and who experienced homelessness in the past year. Participants were randomly assigned (1:1:1:1) by permuted block randomisation, stratified by site, to receive either HaRT-A plus intramuscular injections of 380 mg extended-release naltrexone (XR-NTX; HaRT-A plus XR-NTX group); HaRT-A plus placebo injection (HaRT-A plus placebo group); HaRT-A alone (HaRT-A alone group); or community-based supportive services as usual (services-as-usual control group). Patients assigned to receive HaRT-A attended sessions at baseline (week 0) and in weeks 1, 4, 8, and 12. XR-NTX and placebo injections were administered in weeks 0, 4, and 8. During the study, participants, interventionists, and investigators were masked to group assignment in the two injection arms. All participants were invited to follow-up assessments at weeks 4, 8, 12, 24, and 36. The primary outcomes were self-reported alcohol use quantity (ie, alcohol quantity consumed on peak drinking occasion, as measured with the Alcohol Quantity Use Assessment questionnaire) and frequency (measured with the Addiction Severity Index), alcohol-related harm (measured with the Short Inventory of Problems-2R questionnaire), and physical and mental health-related quality of life (measured with the Short Form-12 survey). Using piecewise growth modelling and an intention-to-treat model, we compared the effects of the three active treatment groups with the services-as-usual control group, and the HaRT-A plus XR-NTX group with the HaRT-A plus placebo group, over the 12-week treatment course and during the 24 weeks following treatment withdrawal. Safety analyses were done on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, NCT01932801.Between Oct 14, 2013, and Nov 30, 2017, 417 individuals experiencing homelessness and alcohol use disorder were screened, of whom 308 were eligible and randomly assigned to the HaRT-A plus XR-NTX group (n=74), the HaRT-A plus placebo group (n=78), the HaRT-A alone group (n=79), or the services-as-usual control group (n=77). Compared with the services-as-usual control group, the HaRT-A plus XR-NTX group showed significant improvements from baseline to 12 weeks post-treatment across four of the five primary outcomes: peak alcohol quantity (linear B -0·48 [95% CI -0·79 to -0·18] p=0·010; full model Cohen's d=-0·68), alcohol frequency (linear B -4·42 [-8·09 to -0·76], p=0·047; full model Cohen's d=-0·16), alcohol-related harm (linear B -2·22 [-3·39 to -1·06], p=0·002; full model Cohen's d=-0·56), and physical health-related quality of life (linear B 0·66 [0·23 to 1·10], p=0·012; full model Cohen's d=0·43). Compared with the services-as-usual control group, the HaRT-A plus placebo group showed significant improvements in three of the five primary outcomes: peak alcohol quantity (linear B -0·41 [95% CI -0·67 to -0·15] p=0·010; full model Cohen's d=-0·23), alcohol frequency (linear B -5·95 [-9·72 to -2·19], p=0·009; full model Cohen's d=-0·13), and physical health-related quality of life (linear B 0·53 [0·09 to 0·98], p=0·050; full model Cohen's d=0·35). Compared with the services-as-usual control group, the HaRT-A alone group showed significant improvements in two of the five primary outcomes: alcohol-related harm (linear B -1·58 [95% CI -2·73 to -0·42] p=0·025; full model Cohen's d=-0·40) and physical health-related quality of life (linear B 0·63 [0·18 to 1·07], p=0·020; full model Cohen's d=0·41). After treatment discontinuation at 12 weeks, the active treatment groups plateaued, whereas the services-as-usual group showed improvements. Thus, during the post-treatment period (weeks 12 to 36), the services-as-usual control group showed greater reductions in alcohol-related harm compared with both the HaRT-A plus XR-NTX group (linear B 0·96 [0·24 to 1·67], p=0·028; full model Cohen's d=0·24) and the HaRT-A alone group (linear B 1·02 [0·35 to 1·70], p=0·013; full model Cohen's d=0·26). During the post-treatment period, the services-as-usual control group significantly improved on mental health-related quality of life compared with the HaRT-A alone group (linear B -0·46 [-0·79 to -0·12], p=0·024; full model Cohen's d=-0·28), and on physical health-related quality of life compared with the HaRT-A plus XR-NTX group (linear B -0·42 [-0·67 to -0·17], p=0·006; full model Cohen's d=-0·27), the HaRT-A plus placebo group (linear B -0·42 [-0·69 to -0·15], p=0·009; full model Cohen's d=-0·27), and the HaRT-A alone group (linear B -0·47 [-0·72 to -0·22], p=0·002; full model Cohen's d=-0·31). For all other primary outcomes, there were no significant linear differences between the services-as-usual and active treatment groups. When comparing the HaRT-A plus placebo group with the HaRT-A plus XR-NTX group, there were no significant differences for any of the primary outcomes. Missing data analysis indicated that participants were more likely to drop out in the services-as-usual control group than in the active treatment groups; however, primary outcome findings were found to be robust to attrition. Participants in the HaRT-A plus XR-NTX, HaRT-A plus placebo, and HaRT-A alone groups were not more likely to experience adverse events than those in the services-as-usual control group.Compared with existing services, combined pharmacological and behavioural harm-reduction treatment resulted in decreased alcohol use and alcohol-related harm and improved physical health-related quality of life during the 12-week treatment period for people experiencing homelessness and alcohol use disorder. Although not as consistent, there were also positive findings for behavioural harm-reduction treatment alone. Considering the non-significant differences between participants receiving HaRT-A plus placebo and HaRT-A plus XR-NTX, the combined pharmacological and behavioural treatment effect cannot be attributed to XR-NTX alone. Future studies are needed to further investigate the relative contributions of the pharmacological and behavioural components of harm-reduction treatment for alcohol use disorder, and to ascertain whether a maintenance treatment approach could extend these positive outcome trajectories.National Institute on Alcohol Abuse and Alcoholism." @default.
- W3135551605 created "2021-03-15" @default.
- W3135551605 creator A5001747997 @default.
- W3135551605 creator A5019760105 @default.
- W3135551605 creator A5029525341 @default.
- W3135551605 creator A5032961089 @default.
- W3135551605 creator A5034508303 @default.
- W3135551605 creator A5036331526 @default.
- W3135551605 creator A5062948417 @default.
- W3135551605 creator A5073577565 @default.
- W3135551605 creator A5079829436 @default.
- W3135551605 date "2021-04-01" @default.
- W3135551605 modified "2023-10-17" @default.
- W3135551605 title "Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial" @default.
- W3135551605 cites W1555759070 @default.
- W3135551605 cites W1606808937 @default.
- W3135551605 cites W1606827522 @default.
- W3135551605 cites W1678757779 @default.
- W3135551605 cites W1965960172 @default.
- W3135551605 cites W1975271154 @default.
- W3135551605 cites W1976064828 @default.
- W3135551605 cites W1978554514 @default.
- W3135551605 cites W1989347552 @default.
- W3135551605 cites W2011388676 @default.
- W3135551605 cites W2011589251 @default.
- W3135551605 cites W2012283425 @default.
- W3135551605 cites W2023851377 @default.
- W3135551605 cites W2026474495 @default.
- W3135551605 cites W2032958849 @default.
- W3135551605 cites W2038774592 @default.
- W3135551605 cites W2042650381 @default.
- W3135551605 cites W2047186876 @default.
- W3135551605 cites W2063397537 @default.
- W3135551605 cites W2064905943 @default.
- W3135551605 cites W2071656003 @default.
- W3135551605 cites W2076078537 @default.
- W3135551605 cites W2078761134 @default.
- W3135551605 cites W2079257116 @default.
- W3135551605 cites W2083060011 @default.
- W3135551605 cites W2086730289 @default.
- W3135551605 cites W2099891228 @default.
- W3135551605 cites W2101372918 @default.
- W3135551605 cites W2107329907 @default.
- W3135551605 cites W2110117912 @default.
- W3135551605 cites W2122706204 @default.
- W3135551605 cites W2127025881 @default.
- W3135551605 cites W2128336124 @default.
- W3135551605 cites W2131293901 @default.
- W3135551605 cites W2133661531 @default.
- W3135551605 cites W2141536144 @default.
- W3135551605 cites W2148583169 @default.
- W3135551605 cites W2151727037 @default.
- W3135551605 cites W2162324554 @default.
- W3135551605 cites W2162691488 @default.
- W3135551605 cites W2172151487 @default.
- W3135551605 cites W2191252001 @default.
- W3135551605 cites W2285114321 @default.
- W3135551605 cites W2404183638 @default.
- W3135551605 cites W2415717114 @default.
- W3135551605 cites W2549773545 @default.
- W3135551605 cites W2790208997 @default.
- W3135551605 cites W2906092499 @default.
- W3135551605 cites W2922265642 @default.
- W3135551605 cites W2971319118 @default.
- W3135551605 doi "https://doi.org/10.1016/s2215-0366(20)30489-2" @default.
- W3135551605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33713622" @default.
- W3135551605 hasPublicationYear "2021" @default.
- W3135551605 type Work @default.
- W3135551605 sameAs 3135551605 @default.
- W3135551605 citedByCount "23" @default.
- W3135551605 countsByYear W31355516052021 @default.
- W3135551605 countsByYear W31355516052022 @default.
- W3135551605 countsByYear W31355516052023 @default.
- W3135551605 crossrefType "journal-article" @default.
- W3135551605 hasAuthorship W3135551605A5001747997 @default.
- W3135551605 hasAuthorship W3135551605A5019760105 @default.
- W3135551605 hasAuthorship W3135551605A5029525341 @default.
- W3135551605 hasAuthorship W3135551605A5032961089 @default.
- W3135551605 hasAuthorship W3135551605A5034508303 @default.
- W3135551605 hasAuthorship W3135551605A5036331526 @default.
- W3135551605 hasAuthorship W3135551605A5062948417 @default.
- W3135551605 hasAuthorship W3135551605A5073577565 @default.
- W3135551605 hasAuthorship W3135551605A5079829436 @default.
- W3135551605 hasBestOaLocation W31355516052 @default.
- W3135551605 hasConcept C118552586 @default.
- W3135551605 hasConcept C126322002 @default.
- W3135551605 hasConcept C138816342 @default.
- W3135551605 hasConcept C15744967 @default.
- W3135551605 hasConcept C159110408 @default.
- W3135551605 hasConcept C168563851 @default.
- W3135551605 hasConcept C170493617 @default.
- W3135551605 hasConcept C185592680 @default.
- W3135551605 hasConcept C2777363581 @default.
- W3135551605 hasConcept C2777972943 @default.
- W3135551605 hasConcept C2779436514 @default.
- W3135551605 hasConcept C2779442783 @default.
- W3135551605 hasConcept C2779992327 @default.
- W3135551605 hasConcept C2781063702 @default.